In a patient with signs of fluid overload and kidney injury, which therapy is most definitive?

Prepare for the NBME Form 9 Test with our engaging quiz. Utilize multiple choice questions and explanations. Excel in your exam with thorough study tools and resources!

Multiple Choice

In a patient with signs of fluid overload and kidney injury, which therapy is most definitive?

Explanation:
When the kidneys are acutely injured and cannot excrete water and wastes, the treatment that most definitively replaces their function is hemodialysis. It mechanically removes excess fluid and uremic solutes and helps correct electrolyte and acid-base disturbances, providing rapid relief from volume overload and toxin buildup even if the kidneys won’t respond to medications alone. Intravenous diuretics might help if there is some remaining renal function, but they are not definitive in AKI and can be ineffective or harmful when the injury is severe. ACE inhibitors can decrease kidney perfusion further in AKI and are not appropriate as rescue therapy here. Oral hydration would worsen fluid overload. Thus, dialysis directly substitutes the failed filtration role of the kidneys and is the most definitive option in this scenario.

When the kidneys are acutely injured and cannot excrete water and wastes, the treatment that most definitively replaces their function is hemodialysis. It mechanically removes excess fluid and uremic solutes and helps correct electrolyte and acid-base disturbances, providing rapid relief from volume overload and toxin buildup even if the kidneys won’t respond to medications alone. Intravenous diuretics might help if there is some remaining renal function, but they are not definitive in AKI and can be ineffective or harmful when the injury is severe. ACE inhibitors can decrease kidney perfusion further in AKI and are not appropriate as rescue therapy here. Oral hydration would worsen fluid overload. Thus, dialysis directly substitutes the failed filtration role of the kidneys and is the most definitive option in this scenario.

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy